Skip to main content
TipRanks
Go Ultimate75% OFF

Allergy Therapeutics (AGYTF) AI Stock Analysis

2 Followers
AGYTF

Allergy Therapeutics

(Other OTC:AGYTF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Underlying-cause allergy treatmentsA focus on allergy immunotherapy and diagnosis addresses the underlying disease rather than providing only symptom relief. That positioning can support differentiated products, recurring clinical demand, and a clearer specialty-pharmaceutical role over the next several quarters.
Negative Factors
Severe profitability deteriorationThe sharp gross-margin compression and very deep net losses indicate that revenue is currently converting into substantially weaker earnings than in 2021. Unless margins recover, the company will struggle to fund growth internally and may remain dependent on external capital.

Allergy Therapeutics (AGYTF) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%AGYTF+27.27%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$88.66M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.6
Beta (1Y)
-2.13
Revenue Growth
12.84%
EPS Growth
-10.09%
Country
US
Employees
584
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Allergy Therapeutics Business Overview & Revenue Model

Company Description

Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside dia...

Allergy Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AGYTF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:HIKGB:HIK74OutperformGBP 3.47B12.3815.05%3.76%2.48%3.36%
GB:VLGGB:VLG65NeutralGBP 82.26M15.827.82%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:STXGB:STX43NeutralGBP 32.76M-4.0964.57%―36.19%60.75%

* Healthcare Sector Average

Performance Comparison

-50%0%50%AGYTFGB:HIKGB:STXGB:VLGGB:BXPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AGYTF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AGYTFAllergy Therapeutics0.140.0327.27%
GB:HIKHikma Pharmaceuticals1685.00190.7012.76%
GB:STXShield Therapeutics3.05-3.70-54.81%
GB:VLGVenture Life69.0010.0016.95%
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS57.5020.2954.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.